Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 5.00 (3.33%)
Spread: 10.00 (6.667%)
Open: 150.00
High: 155.00
Low: 155.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Thomas Cook Plunges On Rescue Deal Talks

Fri, 12th Jul 2019 10:35

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------BHP Group, up 1.5%. The Anglo-Australian miner was upgraded to Neutral from Underweight by JPMorgan. ----------FTSE 100 - LOSERS----------Hiscox, down 5.0%. The insurer said pretax profit for the first half of 2019 is estimated to be between USD150 million and USD170 million amid continued deterioration in insurance market from 2018 catastrophe events, including Typhoon Jebi in Japan and Hurricane Michael in the US state of Florida. Hiscox said the scale of deterioration in the market has been significant, with industry loss estimates having increased materially since the two damaging storms. Hiscox has strengthened reserves for prior year claims from Typhoon Jebi, Hurricane Michael, and for the risk excess book by USD40 million. It expects reserve releases in the first half to be materially lower than last year due to the absence of prior-year releases from Hurricanes Harvey, Irma and Maria, which totalled USD25 million.----------FTSE 250 - WINNERS----------Sophos, up 5.0%. The cybersecurity firm said it is well positioned for growth despite swinging to loss in the first quarter of its current financial year. Sophos said it swung to a pretax loss of USD4.0 million for the three months to the end of June compared to a pretax profit of USD7.3 million reported in the first quarter last year. More positively for Sophos, its adjusted operating profit increased to USD24.1 million from USD21.9 million and its renewal rate as of June 30 stood at 118% compared to 115% a year ago. Revenue, meanwhile, increased by 2.7% to USD180.2 million from USD175.5 million year-on-year. Sophos explained that in the first quarter its subscription revenue growth of 10% in constant currency offset an 11% fall in hardware revenue. ----------easyJet, up 2.8%. Berenberg raised the budget airline to Buy from Hold.----------FTSE 250 - LOSERS----------Senior, down 2.3%. Peel Hunt downgraded the aerospace and defence engineer to Hold from Add. ----------Ashmore Group, down 1.5%. The emerging markets-focused asset manager said healthy client activity, good returns from emerging markets and business diversification led to a 7.6% quarter-on-quarter rise in assets under management for the final three months of financial 2019. The company's assets under management increased by USD6.5 billion during the three months to June 30 to USD91.8 billion from USD85.3 billion as at March 31, with net inflows contributing USD3.3 billion and positive investment performance another USD3.2 billion. The rise in assets also was attributed to improved market conditions such as the easing of US and China trade tensions, central banks in Europe and US turning more dovish, and the weakening of the US dollar. However, Peel Hunt cut the stock to Add from Buy after a strong share price performance. The stock is up 40% so far in 2019. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Faron Pharmaceuticals, up 18%. The clinical stage drug developer said its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries. Faron is undertaking the trial to investigate the safety and effectiveness of Clevegen, the company's cancer immunotherapy. Faron reached its planned Clevegen dosing of 10 milligrams per kilogram in June and said this was "well tolerated" by patients. It plans to propose an increase of the test dosage to 20 milligrams per kilogram to the trial's independent data monitoring board. The MATINS study is investigating five cancers: cutaneous melanoma, hepatobiliary, pancreatic, ovarian and colorectal. Altogether these cancers have two million annual cases worldwide. Of the nine patients being studied across three clinical sites in the UK and Finland, two subjects have demonstrated anti-cancer responses. ----------OTHER MAIN MARKET AND AIM - LOSERS----------Thomas Cook, down 43%. Shares in the travel operator hit an all-time of 6.0 pence with almost GBP80 million wiped off its total market value as the company enters rescue deal talks with its largest shareholder Fosun. Chinese investor Fosun, which holds an 18% stake in the group, could offer a GBP750 million cash injection into the company, which has suffered from falling demand for package holidays and high debt. Fosun said that it, along with Thomas Cook's "core lending banks", are considering the proposal to invest capital into the troubled firm. Thomas Cook said the investment - which will likely comprise a capital injection and new financing facilities - will see a reorganisation of the company's Tour Operator and Airline business. This will lead to Fosun owning a "significant" minority interest in Thomas Cook's Airline. The iconic UK high street travel agent added that its 2019 summer programme is 75% sold - slightly ahead of the year before - but its underlying earnings in the second half will be behind the year before due to the "uncertain consumer environment" in the UK. ----------Lookers, down 22%. The car dealer said it expects to see a drop in profit for the first half of 2019, and expects profit for the full year to be below previous expectations. Although trading in the first quarter to the end of March was positive, the second quarter ended June 30 was challenging, as the UK new car market continued its decline with registrations down by 4.6%. In the used car market, weaker demand led to increased margin pressure, especially in June, during which Lookers said it had to take "a disciplined approach" to managing stock. As a result, underlying pretax profit for the six months to the end of June is expected to be GBP32 million, down 25% from GBP43 million a year before. Looking ahead, Lookers expects the challenging conditions to continue into the second half, stoked by continued weakness in UK consumer confidence due to political and economic uncertainty.----------

More News
18 Mar 2022 16:09

UK earnings, trading statements calendar - next 7 days

Monday 21 March 
Photo-Me International PLCFull Year Results
Spectral MD Holdings LtdFull Year Results
Sthree PLCTrading Statement
Tuesday 22 March 
Alliance Pharma PLCFull Year Results
BioPharma Credit PLCFull Year Results
Circassia Group PLCFull Year Results
Diaceutics PLCFull Year Results
Diurnal Group PLCFull Year Results
IQGeo Group PLCFull Year Results
Longboat Energy PLCFull Year Results
Luceco PLCFull Year Results
MaxCyte IncFull Year Results
MP Evans Group PLCFull Year Results
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Real Estate Investors PLCFull Year Results
Sabre Insurance Group PLCFull Year Results
ScS Group PLCHalf Year Results
Softcat PLCHalf Year Results
Staffline Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
Wednesday 23 March 
Dignity PLCFull Year Results
ECSC Group PLCFull Year Results
Henry Boot PLCFull Year Results
Judges Scientific PLCFull Year Results
Pendragon PLCFull Year Results
Saga PLCFull Year Results
SigmaRoc PLCFull Year Results
Thursday 24 March 
Arbuthnot Banking Group PLCFull Year Results
Atalaya Mining PLCFull Year Results
Big Technologies PLCFull Year Results
Biome Technologies PLCFull Year Results
Bonhill Group PLCFull Year Results
Bridepoint Group PLCFull Year Results
CVS Group PLCHalf Year Results
Energean PLCFull Year Results
EnQuest PLCFull Year Results
Eve Sleep PLCFull Year Results
International Public Partnerships LtdFull Year Results
Kin & Carta PLCFull Year Results
Next PLCFull Year Results
Safestyle UK PLCFull Year Results
Secure Trust Bank PLCFull Year Results
Sopheon PLCFull Year Results
Starwood European Real Estate LtdFull Year Results
WAG Payment Solutions PLCFull Year Results
Friday 25 March 
Electrocomponents PLCTrading Statement
Faron Pharmaceuticals LtdFull Year Results
Smiths Group Half Year Results
United Utilities Group PLCTrading Statement
Wickes Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
14 Mar 2022 14:14

IN BRIEF: Faron research sheds light on Covid-linked mutations

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy.

Read more
4 Mar 2022 20:53

TRADING UPDATES: IOG to cut Gazprom ties; wholesale changes at Donegal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Read more
23 Feb 2022 20:11

TRADING UPDATES: BiVictriX expands development; Okyo wins US patent

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
23 Feb 2022 13:37

Faron upbeat on updated data from cancer treatment study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investigating the safety and efficacy of 'bexmarilimab' on Wednesday.

Read more
31 Jan 2022 14:49

EXECUTIVE CHANGES: Anglo Pacific promotes investment head to CEO

EXECUTIVE CHANGES: Anglo Pacific promotes investment head to CEO

Read more
4 Jan 2022 16:10

Marie-Louise Fjallskog tapped as Faron's new chief medical officer

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the appointment of Marie-Louise Fjällskog as its chief medical officer on Tuesday, to be based in Boston, Massachusetts and effective immediately.

Read more
4 Jan 2022 15:54

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Read more
1 Dec 2021 15:59

EXECUTIVE CHANGES: GCP Infrastructure picks Rothschild banker as chair

EXECUTIVE CHANGES: GCP Infrastructure picks Rothschild banker as chair

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
9 Nov 2021 11:23

Faron Pharmaceuticals wins dispute with Rentschler at tribunal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that the arbitration tribunal appointed by the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) had ruled in its favour in its case against Rentschler Biopharma.

Read more
1 Oct 2021 11:45

IN BRIEF: Faron Pharma raises EUR10.5 million in share placing

IN BRIEF: Faron Pharma raises EUR10.5 million in share placing

Read more
30 Sep 2021 18:06

IN BRIEF: Faron Pharma to raise at least EUR8 million via placing

IN BRIEF: Faron Pharma to raise at least EUR8 million via placing

Read more
17 Sep 2021 17:52

IN BRIEF: Faron Pharma hails updated results from Matins study

IN BRIEF: Faron Pharma hails updated results from Matins study

Read more
26 Aug 2021 14:56

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.